Earlier this month, Nobel laureate Alfred Gilman left his role as chief scientific officer of the Cancer Prevention and Research Institute of Texas. He quit in protest over a disregard for peer review.
Can the institute simultaneously support basic research AND nurture companies – or will a conflict of interest undermine the institute? Nature News reports.
Austin-based CPRIT was created in 2007 when Texas voters agreed to a $3-billion initiative that would spend $300 million a year to advance basic research, reduce cancer rates, and nurture Texas companies. A lot of innovative research was funded.
But earlier this year, Gilman criticized a $20-million commercial ‘incubator’ grant awarded without scientific review – at the same time that a set of grants recommended by the scientific council stalled.
The grant was withdrawn for re-review, provisions were made for scientific review of commercial grants, sidelined grants were approved, and a compliance officer was hired. But many scientific reviewers resigned along with Gilman – accusing CPRIT of “hucksterism.”
CPRIT executive director William Gimson agrees that there were “process problems” with the grants – but says that concerns “mostly boil down to the natural conflict that exists between our scientific and commercialization portfolios.”
Experts and officials weigh in:
[Via Nature News]
Image: CPRIT
This post was originally published on Smartplanet.com